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Abstract
Background: The phenomenon of co-localization of transcriptionally upregulated genes showing
similar expression levels is known across all eukaryotic genomes. We recently mapped the Aroclor
1254-regulated transcriptome back onto the genome and provided evidence for the statistically
significant co-localization of regulated genes. They did, however, not always show similar
expression levels, and many of the regulated genes were, in fact, repressed.
Results: In this study, we were able to reproduce this observation with microarray data stemming
from 1) human hepatocytes treated with the gyrase and potential topoisomerase II inhibitor
trovafloxacin, 2) human hepatocytes treated with the topoisomerase II inhibitor doxorubicin and
3) mouse lymphoma cells treated with the topoisomerase II inhibitor etoposide. We found
statistically significant co-localization of regulated gene pairs – induced and repressed – within the
window size of 0–100 kbp. Notably, by using microarray data stemming from lung tissue of a mouse
transgenic line overexpressing the transcription factor c-myc, which served as a negative control,
we found regulated genes to be located with regard to each other nearly in the same way as genes
distributed randomly all over the genome (0–100 kbp).
Conclusion: We suggest topoisomerase II inhibition by Aroclor 1254, trovafloxacin, doxorubicin,
and etoposide to be responsible for significant co-localization of regulated genes through the
inability of the stabilized enzyme complexes to religate DNA. Within the permanently opened
chromatin domains, neighbored genes might be allowed to be regulated. Overexpression of c-myc,
however, does not inhibit topoisomerase II activity. Consequently, the enzyme is able to perform
its normal function of transiently breaking and rejoining the DNA double strand. As a result,
exclusively target genes are regulated.
Background
Since the patterns of gene expression can be studied across
the entire genome, it is known that binding of transcrip-
tion factor complexes to regulatory sequences of genes is
not the only mechanism controlling gene expression. It
has often been shown that genomic location has an
impact on gene expression [1]. Recently, it has been
shown that identical reporter gene constructs integrated at
90 different chromosomal positions varied eightfold in
their expression levels [2]. Furthermore, an intact gene can
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have a pathological phenotype at a novel genomic loca-
tion [3]. Even before whole-genome sequences were avail-
able, some examples were known showing that genes are
not randomly distributed along chromosomes. Co-locali-
zation and co-regulation have been shown for genes with
related functions, as is the case for the rRNA, histone, Hox,
and globin gene clusters. Later, Spellman and Rubin [4]
described a transcriptional profiling study that revealed a
surprising correlation between the organization of genes
along Drosophila chromosomes and their expression lev-
els. Specifically, co-localized genes, consisting of an aver-
age of 15 contiguous genes, show strikingly similar
relative expression levels. These neighbored genes do not
possess related functions. Moreover, the Human Tran-
scriptome Map-integrated high-throughput expression
data measured by SAGE (serial analysis of gene expres-
sion) revealed that the human genome consists of many
domains/clusters of highly and weakly expressed genes
[5]. Such domains/clusters have also been described in
the mouse genome [6]. Highly and weakly expressed
domains differs in gene density, GC content, and length of
the introns, and this might be explained by a tendency for
highly expressed housekeeping genes to cluster [7]. Thus,
there is extensive evidence for the clustering of co-
expressed genes across all major eukaryotic kingdoms.
The physical range of these co-expressed gene clusters in
mammals extends up to 1000 kbp.
We recently mapped the Aroclor 1254-regulated transcrip-
tome back onto the genome in order to get insight into the
large-scale regulation of transcription [8]. We found genes
regulated by Aroclor 1254 – induced and repressed – to be
located much closer to each other than genes distributed
randomly all over the genome, and many regulated gene
pairs were even found to be directly neighbored. This
raised the possibility of the chromatin structure being
involved in large-scale regulation of transcription. We,
therefore, discussed a structural chromatin domain model
in which distinct chromatin domains have been "opened"
as a result of activation of a target gene. In these domains,
the entire neighborhood has the potential of being
expressed through the accessibility of the corresponding
gene promoters for different transcription factors. This
means that, besides being controlled individually, e.g.
through AhR, genes may also be subject to regulation
according to their location within the genome. Notably,
increased chromatin accessibility is just as likely to facili-
tate the binding of repressors as activators, with the result
that some genes would be upregulated and some down-
regulated. On the one hand, this is consistent with our
Aroclor 1254 gene expression data, according to which
both up- and downregulated genes were found in direct
neighborhood. On the other hand though, this is not con-
sistent with the neighborhood of co-regulation as
described above.
Here, we mapped trovafloxacin- and doxorubicin-regu-
lated transcriptomes of human hepatocytes and etopo-
side-regulated transcriptoms of mouse lymphoma cells
back onto the genome and confirmed our previous results
of chromosomal localization of the Aroclor 1254-regu-
lated transcriptome. We found genes regulated by trova-
floxacin, doxorubicin as well as by etoposide – induced
and repressed – to be located much closer to each other
than genes distributed randomly all over the genome (<
100 kbp). By mapping the transcriptome of lung tissue
stemming from a mouse transgenic line overexpressing
the oncogene c-myc back onto the genome, however, we
found regulated genes to be located with regard to each
other like genes distributed randomly all over the genome
(< 100 kbp). Therefore, we suggest that topoisomerase II
inhibition might be the reason for the chromosomal clus-
tering of Aroclor 1254-, trovafloxacin-, doxorubicin-, and
etoposide-regulated genes. This hypothesis explains the
existence of up- and downregulated genes in the direct
neighborhood and is consequently distinguishable from
the observation of the neighborhood of co-regulation
already described in the literature.
Results
We intended to answer the question as to whether dereg-
ulated genes from other gene expression profiles than
from Aroclor 1254-treated human hepatocytes [8] are also
statistically significantly co-localized along the chromo-
somes. Therefore, we used 1) whole-genome microarray
data of human hepatocytes treated with the gyrase and
potential topoisomerase II inhibitor trovafloxacin, and 2)
treated with the anthracycline antibiotic doxorubicin, 3)
whole-genome microarray data of a mouse lymphoma
cell line treated for with the topoisomerase II inhibitor
etoposide which is used as a form of chemotherapy for
different malignancies [9], and 4) whole-genome micro-
array data of lung tissue stemming from a mouse trans-
genic line overexpressing the oncogene c-myc. The
complete Aroclor, c-myc, trovafloxacin and doxorubicin
data have been deposited in NCBI's Gene Expression
Omnibus (GEO) [10]. They are accessible through GEO
Series accession numbers GSE5213, GSE10954 and the
SuperSeries accession number GSE11942. The complete
etoposide data are stored in EBI ArrayExpress [11] and are
accessible through the accession number E-TOXM-5. The
calculation of significant gene lists resulted in 927 dereg-
ulated genes for Aroclor 1254-treated human hepatocytes,
2241 deregulated genes for trovafloxacin-treated human
hepatocytes, 784 deregulated genes for doxorubicin-
treated human hepatocytes, 877 deregulated genes for
etoposide-treated mouse lymphoma cells, and 1205
deregulated genes for lung tissue stemming from a mouse
transgenic line overexpressing the oncogene c-myc. Lists
of respective significantly deregulated genes possessing a
RefSeq accession number were given in Additional File 1.BMC Genomics 2008, 9:324 http://www.biomedcentral.com/1471-2164/9/324
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We calculated specifically the probability by which partic-
ular deregulated genes will occur within DNA windows of
different sizes as compared to the probability of all known
mapped genes (RefSeq transcripts) of the human genome
(NCBI RefSeq 19,360; build 36.2) or of the mouse
genome (NCBI RefSeq 13,517; build 36.1) to occur
within the same DNA windows. RefSeq transcripts which
possess the same gene symbol or the same start site of
transcription and thus being alternatively spliced tran-
scripts were included only once in the analysis, the other
one was skipped.
The results of this analysis are depicted in Table 1. The
numbers of observed pairs of deregulated genes in the dif-
ferent window sizes used and the mean of the numbers of
pairs of genes stemming from the 100 random lists in the
different window sizes used are listed in Table 1. This
table gives also the standard deviations of the mean values
of the random lists, as well as the significances (p-value),
which express the possibility by which such a result would
appear by chance. Significances were calculated by using
the binominal distribution. Green labeling of values in
Table 1 indicates overrepresentation of co-localized gene
pairs within the window sizes 0–50, 50–100, or 100–200
kbp, whereas yellow labeling of values indicates under-
representation of co-localized gene pairs within the win-
dow size 0–50 kbp. Most of the results were shown to be
statistically highly significant. Thus, at least in the window
sizes 0–50 and 50–100 kbp, genes which were regulated
by Aroclor 1254 and doxorubicin and, moreover, in the
window sizes 0–50, 50–100, and 100–200 kbp, genes
which were regulated by trovafloxacin and etoposide were
located much closer to each other than genes distributed
randomly all over the genome. Different from this are the
results for genes which were regulated by overexpression
of c-myc. In the window size 0–50 kbp, genes are located
much further from each other than genes distributed ran-
domly all over the genome, whereas in the window size
50–100 kbp the distances of regulated genes are the same
as of genes distributed randomly, and in the window size
100–200 kbp genes are also located much closer.
The results are depicted graphically in Figures 1 and 2. The
number of distances < 100 kbp between transcription start
sites of two genes stemming from the 100 randomized
gene lists were used to generate a histogram. In all five his-
tograms, a Gaussian distribution with means of ~30 genes
(Aroclor 1254), ~163 genes (trovafloxacin), ~27 genes
(doxorubicin), ~39 genes (etoposide), and ~64 genes (c-
myc) becomes apparent. In addition, the number of dis-
tances < 100 kbp between transcription start sites of two
genes stemming from the respective significant gene list is
Table 1: Number of genes found in different window sizes.
Window sizes 
analyzed [kbp]
Expected number of 
genes (100 
randomized gene 
lists)
Standard deviation Observed number 
of regulated genes
Significance 
(p-value)
Aroclor (599) 0–50 15.07 3.23 34 0.00000857
50–100 13.70 3.97 19 0.03657915
100–200 24.62 4.60 25 0.08103966
Trovafloxacin (1530) 0–50 84.51 9.38 92 0.03045474
50–100 77.16 7.71 110 0.00005667
100–200 127.52 9.30 143 0.01301018
Doxorubicin (580) 0–50 13.33 3.61 21 0.01286883
50–100 13.46 3.59 25 0.00140735
100–200 23.73 4.83 23 0.08357927
Etoposide (704) 0–50 18.89 4.22 43 0.00024071
50–100 18.50 4.44 46 0.00336279
100–200 34.56 4.78 81 0.00065127
c-myc (899) 0–50 30.82 5.36 23 0.02745216
50–100 29.27 5.67 29 0.07500742
100–200 52.18 7.53 60 0.02919296
Comparison of the gene lists resulting from treatment with different topoisomerase II inhibitors or from overexpression of c-myc with the mean of 
100 randomized gene lists. For each window size, the expected number of genes is shown along with the observed number of genes. The expected 
numbers of genes result from the mean of 100 randomized gene lists comprising the same number of genes as the respective regulated gene list. 
Furthermore, the p-value is shown for obtaining such a result by chance using the binominal distribution. Whenever the difference between the 
expected number of genes and the observed number of regulated genes is significant, the corresponding values are marked bold (expected number 
< observed number) or italic (expected number > observed number).BMC Genomics 2008, 9:324 http://www.biomedcentral.com/1471-2164/9/324
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Treatment with topoisomerase II inhibitors and potential topoisomerase II inhibitors: Frequency of the number of distances <  100 kbp between transcription start sites (TSSs) Figure 1
Treatment with topoisomerase II inhibitors and potential topoisomerase II inhibitors: Frequency of the 
number of distances < 100 kbp between transcription start sites (TSSs). The number of distances < 100 kbp 
between TSSs was calculated for 100 randomized gene lists on the one hand and for the different significant gene lists stemming 
from human hepatocytes and mouse lymphoma cells treated with different topoisomerase II inhibitors and potential topoi-
somerase II inhibitors, respectively, on the other hand. The number of distances < 100 kbp between TSSs of the significantly 
regulated genes is marked by a black arrow in the corresponding histograms.
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marked in the histograms by black arrows. In the case of
Aroclor 1254-, trovafloxacin-, etoposide-, and doxoru-
bicin-regulated genes the strong significant deviation
from the Gaussian distribution resulting from the 100
randomized gene lists is obvious (Figure 1). In the case of
c-myc-regulated genes the number of distances < 100 kbp
between TSSs is within the Gaussian distribution (Figure
2).
The regulated genes whose TSSs are located within 100
kbp and their corresponding expression values are marked
yellow in Additional File 1. The file clearly shows that
these gene pairs do not show similar expression levels. In
many cases transcriptionally induced as well as transcrip-
tionally repressed genes occur within 100 kbp.
Discussion
Topoisomerases are ubiquitous enzymes that alter DNA
topology by cleavage and religation of the DNA. Human
topoisomerase II exists as two isoforms, known as topoi-
somerase IIα (174 kDa) and topoisomerase IIβ (182
kDa), which are essential for a number of nuclear proc-
esses, including chromosome condensation, chromatid
separation, and relief of torsional stress during DNA rep-
lication and transcription [12]. Multiple enzymatic activi-
ties are required for the transcriptional initiation. The
enzyme DNA topoisomerase II associates with gene pro-
moter regions and generates breaks in double-stranded
DNA (dsDNA), which are required for the activation of
gene transcription by DNA-binding transcription factors
[13]. These topoisomerases have been shown to be tar-
geted by different topoisomerase poisons, as they stabilize
the enzyme-mediated double-stranded breaks in the DNA
[14].
In order to test for statistically significant chromosomal
co-localization of regulated genes, we used different
whole-genome microarray data. We used four differentBMC Genomics 2008, 9:324 http://www.biomedcentral.com/1471-2164/9/324
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Overexpression of c-myc: Frequency of the number of distances < 100 kbp between transcription start sites (TSSs) Figure 2
Overexpression of c-myc: Frequency of the number of distances < 100 kbp between transcription start sites 
(TSSs). The number of distances < 100 kbp between TSSs was calculated for 100 randomized gene lists on the one hand and 
for the significant gene list stemming from lung tissue of a mouse transgenic line overexpressing the oncogene c-myc on the 
other hand. The number of distances < 100 kbp between TSSs of the significantly regulated genes is marked by a black arrow in 
the histograms.
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microarray data stemming from compound-treatment
experiments: human hepatocytes treated with 1) Aroclor
1254, as published recently [8], with 2) trovafloxacin
[15], with 3) doxorubicin, and with 4) etoposide [9].
These four compounds have a common characteristic:
they may act as topoisomerase II poisons.
A variety of important anticancer drugs kill cells by
increasing cellular levels of topoisomerase II-DNA cleav-
age complex [16]. The anthracycline anticancer drug dox-
orubicin [17] and potent anti-tumor drug etoposide [18]
form a stable ternary complex with DNA and topoisomer-
ase IIα, thereby inhibiting the normal function of the
enzyme. The complexed enzyme is unable to religate
DNA, so that complex formation increases DNA strand
breaks. Most topoisomerase II poisons are believed to
function at the active site of the enzyme via noncovalent
interactions [16].
Recent studies, however, indicate that sulfhydryl-reactive
quinones such as PCB quinones also have the potential to
increase levels of topoisomerase II-mediated DNA cleav-
age [19-21]. It is believed that these compounds act by
adducing amino acid residues that may lie outside the
active site of the enzyme [19,20]. Aroclor 1254 is a well-
known hepatotoxin, consisting of a complex mixture of
polychlorinated biphenyls (PCBs) and thus may being a
potent topoisomerase IIα poison as well [19].
Trovafloxacin is a broad spectrum antibiotic that inhibits
the uncoiling of supercoiled DNA in various bacteria by
blocking the activity of DNA gyrase and topoisomerase IV
[15]. Specific members of this drug family display high
activity against eukaryotic type II topoisomerase, as well
as cultured mammalian cells and in vivo tumor models
[22,23]. It has been discussed by Waring et al. [24], that
trovafloxacin has a higher affinity for eukaryotic polymer-
ase II system than the other quinolone agents tested. This
effect coupled with other factors, such as an inflammatory
response, might result in a hepatotoxic reaction seen with
drug. Furthermore, Liguori et al. [25] performed microar-
ray studies comparing etoposide with trovafloxacin and
demonstrated similar gene expression changes occurring
for topoisomerase II, RNA polymerase I and II, and other
genes involved in transcription and RNA processing. Con-
sequently, the authors suggested that trovafloxacin has aBMC Genomics 2008, 9:324 http://www.biomedcentral.com/1471-2164/9/324
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higher cross-reactivity with the eukaryotic polymerase II
system than the other quinolone agents tested. Moreover,
binding of quinolones to eukaryotic topoisomerases II
has been suggested to contribute to cytotoxicity. Notably,
trovafloxacin showed a cytotoxic effect in mammalian
cells in vitro [26].
In eukaryotes, chromatin structure plays a major role in all
aspects of DNA metabolism including transcription, rep-
lication, and repair. Changes in accessibility of DNA to
nucleases in response to different stimuli reveal that its
structure is dynamic. For instance, it is known that histone
tail acetylation facilitates transcription, because acetylated
histones restrain and stabilize negative supercoils less
tightly than when unmodified [27]. Increased or
decreased torsional strain may alter transcription and may
antagonize or synergize with chromatin modification and
remodeling [28].
Recently, Collins et al. [29] monitored changes in the
basal transcriptional activity for many genes by using
topoisomerase inhibitors. Examined genes displayed an
individualized profile in response to inhibition of topoi-
somerases I and II. Expression changes elicited by camp-
tothecin (topoisomerase I inhibitor) on the one hand and
adriamycin/doxorubicin (topoisomerase II inhibitor) on
the other hand were not equivalent. Camptothecin gener-
ally caused transcription complexes to stall in the midst of
transcription units, while provoking little response at pro-
moters. Adriamycin, in contrast, caused dramatic changes
at or near promoters and prevented transcription. The
authors have discussed different possibilities that might
be involved in the downregulation of diverse genes by
toposiomerase II inhibition, and assume that the distribu-
tion and transmission of torsional strain are disturbed.
Furthermore, through the direct protein-protein interac-
tion of topoisomerase II with transcription factors, the
basal transcription apparatus, or chromatin-modifying or
-remodeling machinery, the expression of specific genes
might be altered. Furthermore, immobilized topoisomer-
ase II-inhibitor-DNA complexes might form a blockade
hindering the movement of transcription elongation
complexes.
Moreover, another study [30] reported stimulation of IRF-
7 gene expression by topoisomerase II inhibitors. The
authors showed by chromatin immunoprecipitation assay
that treatment with the topoisomerase II inhibitor etopo-
side induced association of aceteylated histone 3 with the
promoter of IRF-7 gene, indicating that changes in the
chromatin structure by the topoisomerase II inhibitor
could be responsible for the induction. They further pro-
posed that creation of DNA double strand breaks by
topoisomerase II inhibitors results in relaxation of the
chromatin structure at the IRF-7 promoter and exposure
of the binding sites for the transcription factors already
present in cells.
Only very few genes were regulated in common by Aroclor
1254, doxorubicin and etoposide. Between each two com-
pounds, the numbers of genes regulated in common were
3.7% to 5.5% (see Additional File 1). Although these
compounds may inhibit topoisomerase II they also excert
a number of different reactions as well. Correspondingly,
we would not expect to see more commonality in the reg-
ulated genes. In response to treatment with Aroclor, dox-
orubicin, or etoposide the enzyme DNA topoisomerase II
associates with the corresponding target gene promoter
regions and generates breaks in double-stranded DNA
(dsDNA), to enable activation of gene transcription. The
topoisomerases can be targeted by these agents and stabi-
lize the enzyme-mediated double-stranded breaks in the
DNA. The observed regulation of genes depends on regu-
latory sequences, targeted by transcription factors which
can be activated directly or indirectly by Aroclor 1254,
doxorubicin and etoposide therefore giving rise to indi-
vidual transcript signatures. This agrees well with the fact
that the different compounds show different side effects
(e.g. doxorubicin shows primary cardiac side effects,
including congestive heart failure, dilated cardiomyopa-
thy, whereas Aroclor 1254 elicits skin effects such as chlo-
racne and rashes, and liver damage).
Transcriptional consequences of topoisomerase II inhibi-
tion as transcriptional induction as well as transcriptional
repression of different genes have been described in vari-
ous studies. Chromatin domains, which are the units of
transcriptional competence, are opened through DNA
double strand breaks by topoisomerase II to reduce the
torsional stress for subsequent transcription. Topoisomer-
ase poisons stabilize the enzyme-mediated double-
stranded breaks in the DNA [14]. These chromatin
domains, however, remain opened, because the stabilized
enzyme complex is unable to religate DNA. Through the
direct protein-protein interaction of topoisomerase II
with transcription factors, the basal transcription appara-
tus, or chromatin-modifying or -remodeling machinery,
the expression of specific genes might be altered. Immobi-
lized topoisomerase II inhibitor-DNA complexes might
also form a blockade hindering the movement of tran-
scription elongation complexes. Furthermore, other genes
which are located also in the same opened chromatin
domain now are accessible for transcription factors
already present in cells. Strikingly, the size of chromatin
domains, which are the units of transcriptional compe-
tences, varies from 5 kb to 200 kb [31]. This size corre-
sponds to our results of statistically significant co-
localization of gene pairs regulated by different topoi-
somerase II inhibitors within the window size of 0–100
kbp. This suggestion also corresponds to our findings ofBMC Genomics 2008, 9:324 http://www.biomedcentral.com/1471-2164/9/324
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transcriptionally induced and  repressed genes being
located in direct neighborhood and does not contradict
the phenomenon of co-localization of transcriptionally
induced genes showing similar expression levels, which is
known across all eukaryotic kingdoms.
Furthermore, we used microarray data stemming from
lung tissue of a mouse transgenic line overexpressing the
oncogene c-myc. C-myc is a multifunctional, nuclear
phosphoprotein that plays a role in cell cycle progression,
apoptosis, and cellular transformation. It functions as a
transcription factor that regulates transcription of specific
target genes. Here, topoisomerase II was not influenced
and thus was able to perform its normal function of tran-
siently breaking and rejoining the phosphodiester back-
bone of both strands of the double helix. Through
transient opening of a chromatin domain, only a single
target gene might be regulated. We thus found c-myc-reg-
ulated genes to be located with regard to each other nearly
in the same way as genes distributed randomly all over the
genome (< 100 kbp). This observation confirms our
hypothesis of topoisomerase II inhibition involving statis-
tically significant co-localization of regulated gene pairs –
induced and repressed – within the window size of 0–100
kbp.
Taken together, the results presented in our study have
revealed some interesting features of gene regulation in
the presence of topoisomerase II inhibitors and potential
topoisomerase II inhibitors. We suggest chromosomal co-
localization of genes regulated in response to topoisomer-
ase II poisons to be a direct consequence of topoisomerase
II inhibition. Notably, genes which are located in the
neighborhood of the target gene within a single chroma-
tin domain are allowed to be regulated through the inabil-
ity of the stabilized enzyme complexes to religate DNA. In
contrast, in the case where topoisomerase II was not influ-
enced (c-myc overexpression) the enzyme was able to per-
form its normal function of transiently breaking and
rejoining the DNA double strand, so that only single tar-
get genes could be regulated.
Methods
Cell culture and tissue samples
Human hepatocytes were isolated from specimens
obtained from patients undergoing hepatic resections as
described by Borlak et al. [32]. They were cultured
enclosed between two layers of collagen as described pre-
viously [32]. Prior to exposure, cells were allowed to
recover from the isolation procedure for 4 to 5 days. Cells
were harvested 72 hours after treatment with 100 μg/ml of
trovafloxacin or 5 days after daily treatment with doxoru-
bicin (0.1 μg/ml, 0.172 μM). Human hepatocytes were
treated with Aroclor 1254 as described in Reymann et al.
[8], and mouse lymphoma cells were treated with etopo-
side as described in Newton et al. [9]. C-myc-transgenic
female mice displayed morphological alterations with
varying degree of nuclear atypia, such as bronchiolo-ade-
nomas and bronchiolo-adenocarcinomas. Different
stages of malignant transformation of alveolar epithelium
were observed. In the non-transgenic control animals no
abnormalities in lung tissue were detected, with the excep-
tion of a single animal which showed a slight focal inter-
stitial mononuclear cell infiltration.
Gene expression studies
Transcriptome analyses of trovafloxacin- and doxoru-
bicin-treated primary human hepatocytes and lung tissue
of c-myc-transgenic female mice were done according to
the manufacturer's recommendation (Affymetrix Gene-
Chip® Expression Analysis Technical Manual (Santa Clara,
CA)), using the GeneChip®  Test Arrays, GeneChip®
Human Expression Array HG-U133 plus 2.0, and Gene-
Chip® Mouse Genome 430 2.0. Total RNA was isolated
from the tissues using the RNeasy total RNA isolation kit
(QIAGEN). A second cleanup of isolated RNA was done
using the RNeasy Mini Kit (QIAGEN). RNA was checked
for quantity, purity, and integrity of the 18S and 28S
ribosomal bands by capillary electrophoresis using the
NanoDrop ND-1000 and the Agilent 2100 Bioanalyzer.
1–15 μg of total RNA were used as starting material to pre-
pare cDNA. Synthesis of double-stranded cDNA was done
with the GeneChip® one-cycle cDNA Kit (Affymetrix). The
cleanup of double-stranded cDNA was done using the
GeneChip® Sample Cleanup module (Affymetrix). 12 μl
of cDNA solution were used for in vitro transcription. The
in vitro transcription was performed with the GeneChip®
IVT Labeling Kit (Affymetrix). The total amount of the
reaction product was purified with the GeneChip® Sample
Cleanup module (Affymetrix). Purified cRNA was quanti-
fied and checked for quality using the NanoDrop ND-
1000 and the Agilent 2100 Bioanalyzer. Purified cRNA
was cleaved into fragments of 35–200 bases by metal-
induced hydrolysis. The degree of fragmentation and the
length distribution of the fragmented biotinylated cRNA
were checked by capillary electrophoresis using the Agi-
lent 2100 Bioanalyzer.
10 μg of biotinylated fragmented cRNA were hybridized
onto the GeneChip® array according to the manufacturer's
recommendation. The hybridization was performed for
16 hours at 60 rpm and 45°C in the GeneChip® Hybridi-
zation Oven 640 (Affymetrix). Washing and staining of
the arrays was done on the GeneChip® Fluidics Station
400 (Affymetrix) according to the manufacturer's recom-
mendation. The antibody signal amplification, washing,
and staining protocol (Affymetrix) was used to stain the
arrays with streptavidin R-phycoerythrin (SAPE; Invitro-
gen, USA). To amplify staining, SAPE solution was addedBMC Genomics 2008, 9:324 http://www.biomedcentral.com/1471-2164/9/324
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twice with a biotinylated anti-streptavidin antibody (Vec-
tor Laboratories, CA) staining step in between.
The arrays were scanned using the GeneChip® Scanner
3000. Scanned image files were visually inspected for arti-
facts and then analyzed, each image being scaled to the
same target value for comparison between chips. The
GeneChip® Operating Software (GCOS) was used to con-
trol the fluidics station and the scanner, to capture probe
array data, and to analyze hybridization intensity data.
Default parameters provided in the Affymetrix data analy-
sis software package were applied for analysis. Transcrip-
tome analyses of Aroclor 1254-treated primary human
hepatocytes and etoposide-treated mouse lymphoma cells
are described in Reymann et al. and Newton et al., respec-
tively [8,9].
Data analysis
Four of the datasets used have been deposited in NCBIs
Gene Expression Omnibus (GEO) [10]. They are accessi-
ble through GEO Series accession numbers GSE5213
(Aroclor 1254), GSE10954 (c-myc) and the SuperSeries
accession number GSE11942 (trovafloxacin and doxoru-
bicin). The complete etoposide data are stored in EBI
ArrayExpress [11] and are accessible through the accession
number E-TOXM-5. Affymetrix .CEL files were uploaded
into our database ArrayTrack [33], which is a toxicoge-
nomics software for microarray data management and
analysis. Significant gene lists were prepared in ArrayTrack
by using the t-test, applying the following criteria: Aroclor
1254: as described in Reymann et al., 2006; trovafloxacin:
p-values < 0.05, mean channel intensities > 100, bad flags
<= 2, abs fold-change > 2.5; doxorubicin: p-values < 0.05,
mean channel intensities > 50, bad flags <= 6, abs fold-
change > 1.2; etoposide: p-values < 0.05, mean channel
intensities > 80, bad flags <= 6, abs fold-change > 1.4; c-
myc: p-values < 0.05; mean channel intensities > 80; bad
flags <= 2; abs fold-change > 1.6.
Analysis of chromosomal localization
From all lists of significantly regulated genes, lists of genes
whose chromosomal positions are known and which pos-
sess a RefSeq accession number were created (Additional
File 1). The start positions of transcription of all RefSeq
transcripts of the human genome (= 19,360) and from the
mouse genome (= 13,517) were downloaded from the
NCBI genome browser MapViewer [34]. Out of this data-
set, 100 random lists possessing the same number of Ref-
Seqs as the corresponding significant gene lists were
created. The numbers of pairs of genes for each of the lists
that were located on the same chromosome within a dis-
tance of > 0–50, > 50–100, and > 100–200 (window sizes)
were calculated. The numbers obtained from the lists of
regulated genes were compared with the mean obtained
from the 100 random lists. To determine if the observed
(regulated) numbers of adjacent pairs were significantly
different from those of expected adjacent pairs (100 ran-
dom lists), the binominal distribution, given by the below
formula was used.
In this formula, n is the total number of RefSeq transcripts
in the respective gene lists, p is the probability of a gene
pair to be present in a single window size (expected
number of gene pairs in a single window size/number of
RefSeq transcripts in the respective gene lists), k is the
observed number of gene pairs in a single window size,
and q = 1-p.
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